title: Sequential development of peripheral t-cell lymphoma post immunochemotherapy of diffuse large B cell lymphoma.
abstract: Reports of sequential occurrence of two or more types of lymphoma are rare, especially when they involve different cell lineages. Herein, we report a rare case of sequential development of peripheral t-cell lymphoma following treatment of diffuse large B cell lymphoma. In a 73-year-old Chinese male patient, diffuse large B-cell lymphoma (DLBCL) was diagnosed in September 2011 based on the result of a tongue biopsy. Afterwards, he received rituximab combined with chemotherapy and local radiotherapy. Though he achieved completed remission, he had a new symptom of one enlarged left inguinal lymph node in November of 2015. A new biopsy was then performed. Immunohistochemistry and polymerase chain reaction (PCR) for gene rearrangements proved monoclonal T-cell lymphoma. We didn't detect EBV infection in either of two biopsies, nor any evidence of immune dysfunction complications. Sequential development of B-cell and T-cell malignancy in this patient maybe an example of treatment-related secondary lymphoma.
authors.affiliation: a Department of Oncology , Huadong Hospital Affiliated to Fudan University , Shanghai , P.R. China.
authors.forename: Jing-Wen
authors.initials: JW
authors.lastname: Wang
authors.affiliation: a Department of Oncology , Huadong Hospital Affiliated to Fudan University , Shanghai , P.R. China.
authors.forename: Jia-Yan
authors.initials: JY
authors.lastname: Chen
authors.affiliation: b Department of Pathology , Huadong Hospital Affiliated to Fudan University , Shanghai , P.R. China.
authors.forename: Chen
authors.initials: C
authors.lastname: Lu
authors.affiliation: a Department of Oncology , Huadong Hospital Affiliated to Fudan University , Shanghai , P.R. China.
authors.forename: Xi
authors.initials: X
authors.lastname: Tang
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001706:Biopsy; D002945:Cisplatin / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D020031:Epstein-Barr Virus Infections / Q000175:diagnosis / Q000821:virology; D005047:Etoposide / Q000627:therapeutic use; D015321:Gene Rearrangement; D050438:Genes, Immunoglobulin Heavy Chain / Q000235:genetics*; D004854:Herpesvirus 4, Human / Q000302:isolation & purification; D006801:Humans; D007150:Immunohistochemistry; D008198:Lymph Nodes / Q000473:pathology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000235:genetics / Q000473:pathology / Q000628:therapy* / Q000821:virology; D016411:Lymphoma, T-Cell, Peripheral / Q000175:diagnosis* / Q000209:etiology / Q000473:pathology / Q000628:therapy; D008297:Male; D016609:Neoplasms, Second Primary; D016133:Polymerase Chain Reaction; D011241:Prednisone / Q000627:therapeutic use; D018714:Radiotherapy, Adjuvant; D011948:Receptors, Antigen, T-Cell / Q000235:genetics*; D000069283:Rituximab / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed; D014059:Tongue / Q000473:pathology
chemical_list: D011948:Receptors, Antigen, T-Cell; D003561:Cytarabine; D000069283:Rituximab; D005047:Etoposide; D002945:Cisplatin; D011241:Prednisone
keywords: Diffuse large B-cell lymphoma; discordant lymphoma; peripheral t-cell lymphoma